Key result
RSV vaccination shows no link to increased AF risk versus influenza or Tdap vaccines.
Why the study?
RSV vaccine clinical trials reported higher frequencies of atrial fibrillation in intervention compared with control groups, raising safety concerns.
Does the RSV vaccine increase the risk of new-onset or recurrent atrial fibrillation in older adults compared with influenza or Tdap vaccines?
Cohort
Does the RSV vaccine increase the risk of new-onset or recurrent atrial fibrillation in older adults compared with influenza or Tdap vaccines?
Real-world propensity-matched data suggests the RSV vaccine does not increase the short-term risk of atrial fibrillation in older adults, reassuring against safety signals observed in initial clinical trials.
Answers are grounded in this paper and cite their sources.
Supports short-term AF safety of RSV vaccine in older adults; leaves open need for randomized confirmation.
Respiratory syncytial virus (RSV) vaccine clinical trials reported higher frequencies of atrial fibrillation in intervention compared with control groups. In this large, population-based, propensity-matched study, we found that RSV vaccine was not associated with increased risk of new-onset or recurrent atrial fibrillation within 1-42 days, compared with influenza or tetanus, diphtheria, and pertussis (Tdap) vaccines.
No takes yet. Share an insight, caveat, or question.
Birabaharan et al. (2024) conducted a cohort in Older adults. RSV vaccine vs. Influenza or Tdap vaccines was evaluated on New-onset or recurrent atrial fibrillation. RSV vaccination was not associated with an increased risk of new-onset or recurrent atrial fibrillation within 1-42 days compared with influenza or Tdap vaccines among older adults.
Synapse has enriched 10 related papers. Consider them for comparative context: